Registration number:
Health Currancy Limited
for the Year Ended 30 April 2026
Health Currancy Limited
Contents
|
Company Information |
|
|
Profit and Loss Account |
|
|
Balance Sheet |
|
|
Notes to the Unaudited Financial Statements |
Health Currancy Limited
Company Information
|
Directors |
Dee Fleur Cushman Thomas Haines Wilson |
|
Registered office |
|
|
Accountants |
|
Health Currancy Limited
Profit and Loss Account for the Year Ended 30 April 2026
The above results were derived from continuing operations.
The company has no recognised gains or losses for the year other than the results above.
Health Currancy Limited
(Registration number: 07589098)
Balance Sheet as at 30 April 2026
|
Note |
2026 |
2025 |
|
|
Fixed assets |
|||
|
Investments |
|
|
|
|
Current assets |
|||
|
Stocks |
|
|
|
|
Debtors |
|
|
|
|
Cash at bank and in hand |
|
|
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets |
|
|
|
|
Total assets less current liabilities |
|
|
|
|
Creditors: Amounts falling due after more than one year |
( |
( |
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
137 |
137 |
|
|
Share premium reserve |
337,234 |
337,234 |
|
|
Retained earnings |
(303,223) |
(310,792) |
|
|
Shareholders' funds |
34,148 |
26,579 |
For the financial year ending 30 April 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
|
• |
|
|
• |
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.
Approved and authorised by the
Health Currancy Limited
(Registration number: 07589098)
Balance Sheet as at 30 April 2026
|
......................................... |
Health Currancy Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 April 2026
|
General information |
The company is a private company limited by share capital, incorporated in England .
The address of its registered office is:
These financial statements were authorised for issue by the
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Going concern
The financial statements have been prepared on a going concern basis.
Revenue recognition
Turnover represents net invoiced sales of goods, excluding value added tax.
Foreign currency transactions and balances
Tax
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Health Currancy Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 April 2026
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the periods in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted for substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and asset reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
Computer Equipment 33% on reducing balance.
Intangible assets
Other intangible assets comprise costs associated with the development of the company's website. The costs are amortised over the assets estimated economic life of 3 years.
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.
Health Currancy Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 April 2026
Stocks
Stocks are valued at the lower of costs and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.
|
Staff numbers |
The average number of persons employed by the company (including directors) during the year, was
|
Intangible assets |
|
Other intangible assets |
Total |
|
|
Cost or valuation |
||
|
At 1 May 2025 |
|
|
|
At 30 April 2026 |
|
|
|
Amortisation |
||
|
At 1 May 2025 |
|
|
|
At 30 April 2026 |
|
|
|
Carrying amount |
||
|
At 30 April 2026 |
- |
- |
The aggregate amount of research and development expenditure recognised as an expense during the period is £
Health Currancy Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 April 2026
|
Tangible assets |
|
Office equipment |
Total |
|
|
Cost or valuation |
||
|
At 1 May 2025 |
|
|
|
At 30 April 2026 |
|
|
|
Depreciation |
||
|
At 1 May 2025 |
|
|
|
At 30 April 2026 |
|
|
|
Carrying amount |
||
|
At 30 April 2026 |
- |
- |
|
Investments |
|
2026 |
2025 |
|
|
Investments in subsidiaries |
|
|
Currancy Limited
|
Subsidiaries |
£ |
|
Cost or valuation |
|
|
At 1 May 2025 |
|
|
Revaluation |
|
|
At 30 April 2026 |
|
|
Provision |
|
|
Carrying amount |
|
|
At 30 April 2026 |
|
|
At 30 April 2025 |
|
|
Stocks |
|
2026 |
2025 |
|
|
Finished goods and goods for resale |
|
|
Health Currancy Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 April 2026
|
Debtors |
|
Current |
2026 |
2025 |
|
Trade debtors |
|
|
|
Other debtors |
|
|
|
|
|
Health Currancy Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 April 2026
|
Creditors |
Creditors: amounts falling due within one year
|
Note |
2026 |
2025 |
|
|
Due within one year |
|||
|
Loans and borrowings |
|
|
|
|
Trade creditors |
|
|
|
|
Amounts owed to group undertakings and undertakings in which the company has a participating interest |
|
|
|
|
Taxation and social security |
|
|
|
|
Accruals and deferred income |
|
|
|
|
Other creditors |
|
|
|
|
|
|
Creditors: amounts falling due after more than one year
|
Note |
2026 |
2025 |
|
|
Due after one year |
|||
|
Loans and borrowings |
|
|
|
Share capital |
Allotted, called up and fully paid shares
|
2026 |
2025 |
|||
|
No. |
£ |
No. |
£ |
|
|
Ordinary Shares of £1 each |
137 |
137 |
137 |
137 |
|
Loans and borrowings |
Non-current loans and borrowings
|
2026 |
2025 |
|
|
Bank borrowings |
|
|
|
Other borrowings |
|
|
|
|
|
|
Current loans and borrowings
Health Currancy Limited
Notes to the Unaudited Financial Statements for the Year Ended 30 April 2026
|
2026 |
2025 |
|
|
Bank borrowings |
|
|
|
Related party transactions |
D F Cushman
Directors Loan
Within the creditors figure is the directors loan to the company which was £32,023 (2024: £37,928).
Compound interest on the directors' loan has been accrued at 6% on the loan outstanding at the year end. Repayment in full is due upon the directors discretion.